Market closed

ArriVent BioPharma/$AVBP

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About ArriVent BioPharma

ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Ticker

$AVBP
Trading on

Industry

Biotechnology

Employees

40

AVBP Metrics

BasicAdvanced
$925M
Market cap
-
P/E ratio
-$3.42
EPS
-
Beta
-
Dividend rate
$925M
$34.51
$14.35
143K
19.285
18.688
0.02
0.077
-24.68%
-36.07%
3.33
3.33
-9.44
-89.61%

What the Analysts think about AVBP

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.

AVBP Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AVBP Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AVBP

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ArriVent BioPharma stock?

ArriVent BioPharma (AVBP) has a market cap of $925M as of November 25, 2024.

What is the P/E ratio for ArriVent BioPharma stock?

The price to earnings (P/E) ratio for ArriVent BioPharma (AVBP) stock is 0 as of November 25, 2024.

Does ArriVent BioPharma stock pay dividends?

No, ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders as of November 25, 2024.

When is the next ArriVent BioPharma dividend payment date?

ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders.

What is the beta indicator for ArriVent BioPharma?

ArriVent BioPharma (AVBP) does not currently have a Beta indicator.